Dr. Debbie Chirnomas serves as Vice President of Oncology Clinical Research at Arvinas. Dr. Chirnomas has over 15 years of oncology clinical research expertise and has advanced drug development at both large pharmaceutical and biotech companies. She previously served as the Vice President of Clinical Development and Medical Affairs at Gamida Cell, where she led strategic roles in launch planning and ongoing Phase 3 registrational study efforts. Previously, Dr. Chirnomas worked at Pfizer, where she held several oncology roles, including serving as Global Medical Strategy Head for Xtandi (enzalutamide) and clinical lead on the Mylotarg program ODAC Meeting and BLA filings in US and EU.
During her academic career, Dr. Chirnomas established and directed the Pediatric Bone Marrow Transplant Program at Yale-New Haven Hospital and served as the Medical Director of the Children’s Transplantation Unit. Prior to that, she was the Director of the Thalassemia Program, and a funded clinical researcher and attending physician at Boston Children’s Hospital/Dana Farber Cancer Institute, Division of Pediatric Hematology-Oncology and Hematopoietic Stem Cell Transplantation.
Dr. Chirnomas received her B.A. in Diplomatic History from the University of Pennsylvania, College of Arts and Sciences, and her B.S.E. in Health Care Economics from the University of Pennsylvania, Wharton School. She received her M.D. at the Albert Einstein College of Medicine and completed her M.P.H. at the Harvard School of Public Health, Program of Clinical Effectiveness. Dr. Chirnomas completed her residency and Chief Residency in Pediatrics at Yale, followed by her fellowship in Pediatric Hematology-Oncology at Dana Farber Cancer Institute/Boston Children’s Hospital.
